Treatment of major depressive disorder and treatment resistant depression with 5-MeO-DMT: Impact of 25 years of non-traditional public scientific communication and education on clinical development and commercialization
Psychedelics April 25, 2026 Juliet Meccia, David Casimir, Sisi Li et al.
Over the past 25 years, informal and underground use of 5-MeO-DMT has generated substantial, though underrecognized, knowledge about its potential to alleviate depressive symptoms. Traditional drug development, with structured trials and regulatory milestones, rarely incorporates findings from these alternative routes. Legal and regulatory barriers have delayed formal clinical investigation, while public channels and Indigenous knowledge have driven grassroots support and anecdotal evidence of therapeutic benefit. The article identifies critical communication gaps hindering integration of 5-MeO-DMT into mainstream psychiatry and advocates for transparent data-sharing models that incorporate existing informal knowledge.